Vogenx (NASDAQ:VOGX) Announces Earnings Results

Vogenx (NASDAQ:VOGX) released its earnings results on Friday. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01, Zacks reports.

Vogenx Stock Down 4.3%

Shares of Vogenx stock opened at $17.45 on Friday. Vogenx has a 1 year low of $12.95 and a 1 year high of $38.41. The stock has a 50-day simple moving average of $23.45. The company has a market capitalization of $259.13 million and a P/E ratio of -249.29.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on VOGX shares. JonesTrading started coverage on Vogenx in a research note on Tuesday, September 1st. They issued a “buy” rating and a $55.00 price target on the stock. WBB Securities assumed coverage on Vogenx in a research note on Wednesday, September 2nd. They set a “speculative buy” rating and a $42.00 price objective for the company. Zacks Research raised Vogenx to a “hold” rating in a research note on Monday, September 28th. Finally, Wall Street Zen upgraded Vogenx to a “hold” rating in a report on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $48.50.

Vogenx Company Profile

Vogenx, Inc is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company has historically concentrated on small-molecule drug candidates intended to address conditions in which existing treatment options may be limited.

Vogenx’s lead development program has included VGX-1027, an investigational anti-inflammatory compound studied for its potential to regulate abnormal immune responses. Research involving the candidate has focused on diseases associated with inflammation and immune-system dysfunction, although its development status and commercial availability may change over time.

The company’s activities have primarily involved pharmaceutical research and development rather than the marketing of an established portfolio of products.